Opinion of the Transparency Council – ciclosporin
At its meeting on 10 February 2025, the Transparency Council adopted opinion No. 27/2025 on the reimbursement of medicines containing the active substance ciclosporin for indications, dosages or administration methods other than those specified in the Summary of Product Characteristics, i.e.: bone marrow aplasia or hypoplasia; large granular lymphocyte T-cell leukemia; selective red cell aplasia; macrophage activation syndrome; hemophagocytic syndrome; refractory thrombocytopenia; myelodysplastic syndrome – palliative treatment; condition after transplantation of a limb, cornea, tissue or cells